Immunovant Announces Pricing of $550 Million Common Stock Financing
Immunovant (Nasdaq: IMVT) priced an underwritten common stock offering to raise approximately $550 million of gross proceeds by selling 26.2 million shares at $21.00 per share.
Rhea-AI Summary
Immunovant (Nasdaq: IMVT) priced an underwritten common stock offering to raise approximately $550 million of gross proceeds by selling 26.2 million shares at $21.00 per share. The company said existing cash plus proceeds are expected to fund operating expenses and capital expenditures through a potential commercial launch of IMVT-1402 for Graves’ disease.
Roivant Sciences, the controlling stockholder, agreed to purchase shares. The offering is expected to close on or about December 12, 2025, subject to customary closing conditions, with Leerink Partners as sole underwriter.
Positive
- Gross proceeds of $550 million
- Funds expected to cover operations and capex through potential IMVT-1402 launch
Negative
- Issuance of 26.2 million new shares will dilute existing shareholders
- Net proceeds reduced by underwriting discounts, commissions and offering expenses
Details
News Market Reaction – IMVT
In the Dec 11 session, IMVT gained 5.31%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Gross proceeds
- $550 million
- Anticipated gross proceeds from underwritten common stock offering
- Shares offered
- 26.2 million shares
- Common stock offered in current financing
- Offering price
- $21.00 per share
- Price for the underwritten common stock offering
- Runway scope
- Through potential GD launch
- Company states funding through potential IMVT-1402 Graves’ Disease commercial launch
- Expected closing date
- December 12, 2025
- Target closing date for the underwritten offering
- Lead underwriter
- Leerink Partners
- Acting as sole underwriter for the offering
- Roivant participation
- Roivant to purchase shares
- Controlling stockholder agreed to purchase shares in the offering
- Lead asset
- IMVT-1402
- Funding tied to potential Graves’ Disease commercial launch
Historical Context
-
Quarterly results and IMVT-1402 clinical updates with strong cash position.
-
Announcement of upcoming Q2 results call and access details.
-
Six-month Graves’ remission data and plans for registrational IMVT-1402 trials.
-
Quarter results, new registrational studies, and higher R&D with wider net loss.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
underwritten offering financial
gross proceeds financial
Graves’ Disease medical
automatic registration statement on Form S-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Funding to provide runway through potential Graves’ Disease commercial launch
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately
Immunovant currently expects that its existing cash and cash equivalents, together with the proceeds from the transaction, will be sufficient to fund its operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 in the Graves’ Disease indication.
Immunovant offered 26.2 million shares of its common stock in the offering at an offering price of
Leerink Partners is acting as the sole underwriter for the offering.
The shares in the offering are being offered by Immunovant pursuant to an automatic registration statement on Form S-3 previously filed with the SEC.
When available, a copy of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com.
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “can,” “may,” “might,” “will,” “would,” “should,” “expect,” “believe,” “estimate,” “design,” “plan,” "intend," and other similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, but are not limited to, the uncertainties related to the completion of the offering. All forward-looking statements are based on estimates and assumptions by Immunovant’s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: Immunovant may not be able to protect or enforce its intellectual property rights; initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant’s product candidates, including the number and timing of the commencement of additional clinical trials; Immunovant’s scientific approach, clinical trial design, indication selection, and general development progress; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this press release; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant’s product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the potential impact of global factors, such as international trade tariffs, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chain, including its clinical development plans and timelines; Immunovant’s business is heavily dependent on the successful development, regulatory approval, and commercialization of IMVT-1402; Immunovant is at various stages of clinical development for IMVT-1402 and batoclimab; and Immunovant will require additional capital to fund its operations and advance IMVT-1402 and batoclimab through clinical development. These and other risks and uncertainties are more fully described in Immunovant’s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled “Risk Factors” in Immunovant’s Annual Report on Form 10-K filed with the SEC on May 29, 2025, and Immunovant’s subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com
